Cytokinetics Announces Strategic Restructuring

Cytokinetics has decided to refocus its resources and prioritize development of its later-stage candidates, CK-2017357 for ALS and Omecamtiv Mecarbil for heart failure. The requisite changes in workforce and operations are expected to enable Cytokinetics to advance initiation of a clinical trial of CK-2017357 for ALS. The biotech will retain a smaller, fully integrated R&D capability to continue its follow-on skeletal muscle troponin activator program and certain other muscle biology programs.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail